{"entity":{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","aka":[],"tldr":"C2i Genomics built a blood test that reads the whole genome of tumour DNA fragments to detect leftover cancer after treatment; Veracyte bought the company in 2024 and now sells the approach as TrueMRD.","summary":"C2i Genomics, founded in New York with research roots at the New York Genome Center and the Weizmann Institute, developed a whole-genome approach to minimal residual disease (MRD) detection. Rather than tracking a small targeted panel, it sequences the tumour genome to define thousands of somatic variants and applies AI pattern recognition to low-pass whole-genome sequencing of plasma cell-free DNA, giving sensitive detection from a single blood tube. Veracyte announced a definitive agreement to acquire C2i on 8 January 2024 for $70 million in Veracyte shares at closing plus up to $25 million in performance milestones, extending its diagnostics platform into MRD monitoring. The technology now underpins Veracyte's TrueMRD platform, whose first test, for muscle-invasive bladder cancer, is available to order in the United States, with more cancers planned.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.veracyte.com/innovation/truemrd-platform/"},{"label":"Veracyte 8-K exhibit announcing C2i acquisition (Jan 2024)","url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["c2i-genomics.com redirects to Veracyte. Pre-acquisition venture rounds not sourced. Completion date of the acquisition not separately verified; the 8-K covers the definitive agreement."],"hq":"New York, NY","country":"US","companyType":"diagnostics","website":"https://www.veracyte.com/innovation/truemrd-platform/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2024,"amountUsd":70000000,"source":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm","note":"$70 million in Veracyte shares at closing plus up to $25 million in milestone payments over two years; definitive agreement announced 8 January 2024."}],"acquiredBy":"veracyte"},"route":"/companies/c2i-genomics/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/"}]}}